MHE Week in Review – Regenerative Medicine for Vitiligo, Pain Patch Potential

Conventional drug development typically zeroes in on individual proteins or signaling pathways. By focusing on the transcription factor FOXO3, Refoxy hopes to harness a key regulator that impacts numerous biological processes.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

By narrowing their research to overweight and obese individuals, Roswell Park researchers found that metformin might offer benefits that previous trials overlooked.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly therapy and the first specifically approved for cardiomyopathy in patients with Duchenne muscular dystrophy.

The year's top conference coverage item shares the effects of "Ozempic Bod" and "Ozempic Face," as presented at the annual American Academy of Ophthalmology meeting in Chicago.